| 693 | Humans |
| 511 | Female |
| 410 | Male |
| 393 | Adult |
| 275 | Adolescent |
| 266 | Ghana |
| 235 | Middle Aged |
| 216 | Ghana (epidemiology) |
| 151 | Young Adult |
| 144 | HIV Infections (epidemiology) |
| 128 | HIV Infections (prevention & control) |
| 118 | Child |
| 112 | Cross-Sectional Studies |
| 111 | Prevalence |
| 95 | Health Knowledge, Attitudes, Practice |
| 88 | Risk Factors |
| 86 | Developing Countries |
| 85 | HIV Infections (drug therapy) |
| 82 | Infant |
| 78 | Pregnancy |
| 77 | HIV Infections (transmission) |
| 76 | Child, Preschool |
| 72 | HIV Infections (complications) |
| 71 | Aged |
| 66 | HIV Infections (psychology) |
| 66 | Africa |
| 59 | Surveys and Questionnaires |
| 59 | Africa South of the Sahara |
| 54 | Socioeconomic Factors |
| 49 | HIV Infections |
| 47 | Infant, Newborn |
| 46 | Sexual Behavior |
| 46 | Africa, Western |
| 44 | Anti-HIV Agents (therapeutic use) |
| 42 | HIV Infections (virology) |
| 39 | Disease |
| 38 | HIV Infections (diagnosis) |
| 38 | CD4 Lymphocyte Count |
| 37 | Virus Diseases |
| 36 | Retrospective Studies |
| 36 | HIV-1 (genetics) |
| 35 | Acquired Immunodeficiency Syndrome |
| 31 | Demography |
| 30 | Treatment Outcome |
| 30 | Molecular Sequence Data |
| 29 | South Africa (epidemiology) |
| 29 | Rural Population |
| 29 | HIV Infections (immunology) |
| 29 | Condoms (utilization) |
| 28 | HIV-1 |
| 27 | Seroepidemiologic Studies |
| 27 | Age Factors |
| 27 | Africa South of the Sahara (epidemiology) |
| 27 | Acquired Immunodeficiency Syndrome (epidemiology) |
| 26 | Population Surveillance |
| 26 | Phylogeny |
| 26 | Logistic Models |
| 26 | Cause of Death |
| 25 | Sex Factors |
| 25 | Risk-Taking |
| 25 | Family Planning Services |
| 25 | Acquired Immunodeficiency Syndrome (prevention & control) |
| 24 | Health Surveys |
| 24 | HIV Infections (blood) |
| 24 | Genotype |
| 23 | Time Factors |
| 23 | Case-Control Studies |
| 23 | Acquired Immunodeficiency Syndrome (psychology) |
| 22 | Sexual Behavior (psychology) |
| 22 | Incidence |
| 22 | Attitude to Health |
| 22 | Anti-Retroviral Agents (therapeutic use) |
| 21 | Viral Load |
| 21 | Prospective Studies |
| 21 | Economics |
| 20 | Sensitivity and Specificity |
| 20 | Interviews as Topic |
| 20 | Health Education |
| 20 | Educational Status |
| 19 | Qualitative Research |
| 19 | Health Planning |
| 19 | HIV-1 (isolation & purification) |
| 19 | HIV Seropositivity (epidemiology) |
| 19 | Focus Groups |
| 18 | Sex Work |
| 18 | Population |
| 18 | Behavior |
| 18 | Aged, 80 and over |
| 18 | Africa (epidemiology) |
| 17 | Sexually Transmitted Diseases (prevention & control) |
| 17 | Research |
| 17 | Program Evaluation |
| 17 | Poverty |
| 17 | Hospitals, Teaching |
| 17 | Hepatitis B (epidemiology) |
| 17 | HIV-1 (immunology) |
| 17 | HIV Seroprevalence |
| 17 | HIV Infections (mortality) |
| 17 | HIV Antibodies (blood) |
| 17 | Ghana (ethnology) |
| 16 | Stereotyping |
| 16 | Sexual Behavior (statistics & numerical data) |
| 16 | Sequence Analysis, DNA |
| 16 | Organization and Administration |
| 16 | Health Services Needs and Demand |
| 16 | Family Characteristics |
| 16 | Education |
| 16 | Counseling |
| 16 | Condoms |
| 16 | Comorbidity |
| 16 | Communication |
| 16 | Blood Donors |
| 16 | Antiretroviral Therapy, Highly Active |
| 15 | Social Support |
| 15 | Sexual Partners |
| 15 | Patient Acceptance of Health Care (statistics & numerical data) |
| 15 | Multivariate Analysis |
| 15 | Mass Screening |
| 15 | International Cooperation |
| 15 | Health Services Accessibility |
| 15 | HIV-2 (genetics) |
| 15 | Culture |
| 15 | Cohort Studies |
| 14 | Odds Ratio |
| 14 | HIV-1 (drug effects) |
| 14 | HIV-1 (classification) |
| 14 | Base Sequence |
| 14 | Anti-HIV Agents (administration & dosage) |
| 13 | World Health Organization |
| 13 | Residence Characteristics |
| 13 | Population Characteristics |
| 13 | Mass Screening (methods) |
| 13 | Infectious Disease Transmission, Vertical (prevention & control) |
| 13 | Health Behavior |
| 13 | HIV-2 |
| 13 | HIV Infections (genetics) |
| 13 | Enzyme-Linked Immunosorbent Assay |
| 13 | Emigration and Immigration |
| 13 | Coinfection (epidemiology) |
| 13 | Asia |
| 13 | Antiretroviral Therapy, Highly Active (methods) |
| 13 | Antibodies, Viral (blood) |
| 13 | Animals |
| 13 | AIDS-Related Opportunistic Infections (epidemiology) |
| 12 | Urban Population |
| 12 | Social Stigma |
| 12 | Risk Assessment |
| 12 | Reproducibility of Results |
| 12 | Peer Group |
| 12 | Longitudinal Studies |
| 12 | Infection |
| 12 | Hepatitis C (epidemiology) |
| 12 | Health Policy |
| 12 | Follow-Up Studies |
| 12 | Contraception |
| 12 | Age Distribution |
| 12 | Acquired Immunodeficiency Syndrome (transmission) |
| 11 | Sexually Transmitted Diseases |
| 11 | Sexual Behavior (ethnology) |
| 11 | Sex Distribution |
| 11 | Severity of Illness Index |
| 11 | RNA, Viral (blood) |
| 11 | Pregnancy Complications, Infectious (epidemiology) |
| 11 | Population Dynamics |
| 11 | Polymerase Chain Reaction |
| 11 | Organizations |
| 11 | Nigeria |
| 11 | Interpersonal Relations |
| 11 | Health |
| 11 | HIV-2 (immunology) |
| 11 | HIV Infections (economics) |
| 11 | Genetic Variation |
| 11 | Data Collection |
| 11 | Coinfection |
| 11 | Anti-HIV Agents (adverse effects) |
| 11 | Amino Acid Sequence |
| 11 | Africa, Western (epidemiology) |
| 11 | Africa, Eastern |
| 10 | Uganda |
| 10 | Tuberculosis, Pulmonary (complications) |
| 10 | Tuberculosis (epidemiology) |
| 10 | Tuberculosis (drug therapy) |
| 10 | Sexually Transmitted Diseases (epidemiology) |
| 10 | Rural Population (statistics & numerical data) |
| 10 | Rural Health |
| 10 | Reproductive Medicine |
| 10 | Regression Analysis |
| 10 | Pilot Projects |
| 10 | Perception |
| 10 | Mortality (trends) |
| 10 | Microbial Sensitivity Tests |
| 10 | HIV-2 (isolation & purification) |
| 10 | DNA, Viral (genetics) |
| 10 | CD4-Positive T-Lymphocytes (immunology) |
| 10 | Antitubercular Agents (therapeutic use) |
| 10 | Antimalarials (therapeutic use) |
| 10 | Algorithms |
| 9 | South Africa |
| 9 | Sexual Partners (psychology) |
| 9 | Risk |
| 9 | Recombination, Genetic |
| 9 | Prejudice |
| 9 | Politics |
| 9 | Malaria (prevention & control) |
| 9 | Kenya |
| 9 | Kenya (epidemiology) |
| 9 | Hepatitis B Surface Antigens (blood) |
| 9 | Health Personnel |
| 9 | Health Education (methods) |
| 9 | HIV Seropositivity (diagnosis) |
| 9 | HIV Infections (therapy) |
| 9 | HIV Infections (physiopathology) |
| 9 | HIV Infections (ethnology) |
| 9 | Double-Blind Method |
| 9 | Disease Outbreaks |
| 9 | Delivery of Health Care |
| 9 | Cost-Benefit Analysis |
| 9 | Blotting, Western |
| 9 | Blood Transfusion (adverse effects) |
| 9 | Autopsy |
| 9 | Adolescent Behavior (psychology) |
| 9 | Acquired Immunodeficiency Syndrome (immunology) |
| 9 | AIDS-Related Opportunistic Infections (microbiology) |
| 8 | Urban Health |
| 8 | United Nations |
| 8 | Survival Analysis |
| 8 | Sex Education |
| 8 | Program Development |
| 8 | Pregnancy Complications, Infectious (prevention & control) |
| 8 | Patient Acceptance of Health Care |
| 8 | Malaria (epidemiology) |
| 8 | International Agencies |
| 8 | Infectious Disease Transmission, Vertical |
| 8 | Hospitalization (statistics & numerical data) |
| 8 | Hepatitis C Antibodies (blood) |
| 8 | Hepatitis B (prevention & control) |
| 8 | HIV-1 (physiology) |
| 8 | HIV Seropositivity (immunology) |
| 8 | Global Health |
| 8 | Evaluation Studies as Topic |
| 8 | Drug Therapy, Combination |
| 8 | Databases, Factual |
| 8 | Data Collection (methods) |
| 8 | Body Mass Index |
| 8 | Adolescent Behavior |
| 8 | Acquired Immunodeficiency Syndrome (mortality) |
| 8 | Acquired Immunodeficiency Syndrome (ethnology) |
| 8 | Acquired Immunodeficiency Syndrome (drug therapy) |
| 7 | Zimbabwe |
| 7 | Zambia (epidemiology) |
| 7 | Women's Health |
| 7 | Viral Load (drug effects) |
| 7 | Tuberculosis (prevention & control) |
| 7 | Tuberculosis (complications) |
| 7 | Transients and Migrants |
| 7 | Tanzania (epidemiology) |
| 7 | Syphilis (epidemiology) |
| 7 | Social Class |
| 7 | Self Efficacy |
| 7 | Predictive Value of Tests |
| 7 | Patient Acceptance of Health Care (psychology) |
| 7 | Motivation |
| 7 | Molecular Epidemiology |
| 7 | Models, Statistical |
| 7 | Marriage |
| 7 | Hospitalization |
| 7 | Hepatitis C (transmission) |
| 7 | Health Status |
| 7 | Health Promotion (methods) |
| 7 | HIV-2 (classification) |
| 7 | HIV Seropositivity (virology) |
| 7 | HIV Seropositivity (psychology) |
| 7 | HIV Seropositivity (complications) |
| 7 | HIV Seropositivity (blood) |
| 7 | Financial Management |
| 7 | Disease Progression |
| 7 | Diet |
| 7 | Cultural Characteristics |
| 7 | Cluster Analysis |
| 7 | Burkina Faso |
| 7 | Attitude of Health Personnel |
| 7 | Antiretroviral Therapy, Highly Active (adverse effects) |
| 7 | Ambulatory Care Facilities |
| 7 | Africa, Northern |
| 7 | Acquired Immunodeficiency Syndrome (virology) |
| 7 | AIDS Serodiagnosis (utilization) |
| 6 | Urban Population (statistics & numerical data) |
| 6 | Unsafe Sex |
| 6 | Universities |
| 6 | United States |
| 6 | Tuberculosis (diagnosis) |
| 6 | Tanzania |
| 6 | Students (psychology) |
| 6 | Sequence Alignment |
| 6 | Sentinel Surveillance |
| 6 | Senegal |
| 6 | Seasons |
| 6 | Reverse Transcriptase Polymerase Chain Reaction |
| 6 | Research Design |
| 6 | Public Policy |
| 6 | Public Health |
| 6 | Proportional Hazards Models |
| 6 | Pregnancy Complications, Infectious (drug therapy) |
| 6 | Pregnancy Complications, Infectious (diagnosis) |
| 6 | Practice Guidelines as Topic |
| 6 | Population Surveillance (methods) |
| 6 | Phenotype |
| 6 | Mothers |
| 6 | Morbidity |
| 6 | Malaria (drug therapy) |
| 6 | Japan |
| 6 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
| 6 | Infant Mortality |
| 6 | India |
| 6 | Hospitals |
| 6 | Hospital Mortality |
| 6 | Histoplasma (isolation & purification) |
| 6 | Hepatitis C (prevention & control) |
| 6 | Hepatitis B virus (isolation & purification) |
| 6 | Hepatitis B (transmission) |
| 6 | Hepatitis B (blood) |
| 6 | Hemoglobins (analysis) |
| 6 | Health Services Accessibility (statistics & numerical data) |
| 6 | HIV Infections (pathology) |
| 6 | HIV Envelope Protein gp120 (genetics) |
| 6 | Employment |
| 6 | Drug Combinations |
| 6 | Diagnosis, Differential |
| 6 | Developed Countries |
| 6 | DNA, Viral (analysis) |
| 6 | Cote d'Ivoire |
| 6 | Costs and Cost Analysis |
| 6 | Contraception Behavior (statistics & numerical data) |
| 6 | Condoms (statistics & numerical data) |
| 6 | Communicable Diseases (epidemiology) |
| 6 | Burkina Faso (epidemiology) |
| 6 | Antiviral Agents (therapeutic use) |
| 6 | Antifungal Agents (therapeutic use) |
| 6 | Anti-Bacterial Agents (therapeutic use) |
| 6 | Adenine (analogs & derivatives) |
| 6 | Adaptation, Psychological |
| 6 | Acquired Immunodeficiency Syndrome (microbiology) |
| 6 | AIDS-Related Opportunistic Infections (drug therapy) |
| 6 | AIDS-Related Opportunistic Infections (diagnosis) |
| 5 | United Kingdom |
| 5 | Tuberculosis, Pulmonary (epidemiology) |
| 5 | Tuberculosis, Pulmonary (diagnosis) |
| 5 | Truth Disclosure |
| 5 | Tenofovir |
| 5 | Simian Immunodeficiency Virus (genetics) |
| 5 | Self Report |
| 5 | Rotavirus Vaccines (immunology) |
| 5 | Rotavirus Vaccines (administration & dosage) |
| 5 | Rotavirus Infections (prevention & control) |
| 5 | Risk Reduction Behavior |
| 5 | Reverse Transcriptase Inhibitors (therapeutic use) |
| 5 | Religion |
| 5 | RNA, Viral (genetics) |
| 5 | Prognosis |
| 5 | Prenatal Care |
| 5 | Polymorphism, Single Nucleotide |
| 5 | Plant Extracts (pharmacology) |
| 5 | Peptide Fragments (genetics) |
| 5 | Outcome Assessment (Health Care) |
| 5 | Models, Theoretical |
| 5 | Medication Adherence (statistics & numerical data) |
| 5 | Mass Screening (statistics & numerical data) |
| 5 | Malawi |
| 5 | Lamivudine (therapeutic use) |
| 5 | Homosexuality, Male |
| 5 | History, 20th Century |
| 5 | Histoplasmosis (diagnosis) |
| 5 | Hepatitis B virus (genetics) |
| 5 | Hepatitis B (complications) |
| 5 | Health Services Research |
| 5 | Health Priorities |
| 5 | Health Care Surveys |
| 5 | HTLV-I Infections (epidemiology) |
| 5 | HIV |
| 5 | HIV Seropositivity |
| 5 | HIV Seropositivity (ethnology) |
| 5 | HIV (immunology) |
| 5 | Gender Identity |
| 5 | Food Supply |
| 5 | Drug Resistance, Viral |
| 5 | Decision Making |
| 5 | Counseling (utilization) |
| 5 | Cost of Illness |
| 5 | Community Participation |
| 5 | Coinfection (virology) |
| 5 | Coinfection (drug therapy) |
| 5 | Caregivers (psychology) |
| 5 | Blood-Borne Pathogens |
| 5 | Biomarkers (blood) |
| 5 | Autopsy (methods) |
| 5 | Asia (epidemiology) |
| 5 | Artemisinins (therapeutic use) |
| 5 | Anti-Infective Agents (therapeutic use) |
| 5 | Anti-HIV Agents (pharmacology) |
| 5 | Anemia (epidemiology) |
| 5 | Analysis of Variance |
| 5 | Administration, Oral |
| 5 | Acquired Immunodeficiency Syndrome (diagnosis) |
| 5 | Acquired Immunodeficiency Syndrome (complications) |
| 5 | AIDS Serodiagnosis |
| 5 | AIDS Serodiagnosis (methods) |
| 4 | Women |
| 4 | Women's Rights |
| 4 | Women (psychology) |
| 4 | Weight Gain |
| 4 | Vulnerable Populations |
| 4 | Vitamin A (administration & dosage) |
| 4 | Viremia |
| 4 | Viremia (epidemiology) |
| 4 | Vaccines, Attenuated (immunology) |
| 4 | Vaccines, Attenuated (administration & dosage) |
| 4 | Unsafe Sex (statistics & numerical data) |
| 4 | Unsafe Sex (psychology) |
| 4 | Tuberculosis, Pulmonary (mortality) |
| 4 | Tuberculosis, Pulmonary (microbiology) |
| 4 | Tuberculosis, Pulmonary (immunology) |
| 4 | Tuberculosis (psychology) |
| 4 | Tuberculosis (mortality) |
| 4 | Trimethoprim, Sulfamethoxazole Drug Combination (therapeutic use) |
| 4 | Travel |
| 4 | Sputum (microbiology) |
| 4 | Sexually Transmitted Diseases (psychology) |
| 4 | Sex Workers |
| 4 | Sex Workers (statistics & numerical data) |
| 4 | Sequence Homology, Nucleic Acid |
| 4 | Sequence Homology, Amino Acid |
| 4 | Schools |
| 4 | Sampling Studies |
| 4 | Safe Sex (statistics & numerical data) |
| 4 | Respiratory Tract Infections (virology) |
| 4 | Respiratory Tract Infections (epidemiology) |
| 4 | Reagent Kits, Diagnostic |
| 4 | RNA, Viral (analysis) |
| 4 | Quality of Life |
| 4 | Quality of Health Care |
| 4 | Prenatal Care (standards) |
| 4 | Pregnancy Outcome |
| 4 | Pregnancy Complications, Infectious |
| 4 | Pregnancy Complications, Infectious (virology) |
| 4 | Polymorphism, Genetic |
| 4 | Point-of-Care Systems |
| 4 | Patient Education as Topic |
| 4 | Parents (psychology) |
| 4 | Organophosphonates (administration & dosage) |
| 4 | Nutritional Status |
| 4 | Nigeria (epidemiology) |
| 4 | Needs Assessment |
| 4 | Nasopharynx (microbiology) |
| 4 | Mycobacterium tuberculosis (isolation & purification) |
| 4 | Mycobacterium tuberculosis (drug effects) |
| 4 | Mutation |
| 4 | Mothers (psychology) |
| 4 | Models, Psychological |
| 4 | Medication Adherence |
| 4 | Maternal Welfare |
| 4 | Maternal Mortality |
| 4 | Mass Media |
| 4 | Marriage (statistics & numerical data) |
| 4 | Mali (epidemiology) |
| 4 | Malaria (diagnosis) |
| 4 | Malaria (complications) |
| 4 | Malaria (blood) |
| 4 | Lamivudine (administration & dosage) |
| 4 | Intention |
| 4 | Information Services |
| 4 | Influenza, Human (epidemiology) |
| 4 | Income |
| 4 | Immunoglobulin M (blood) |
| 4 | Immunoglobulin G (blood) |
| 4 | Immunoenzyme Techniques |
| 4 | History, 21st Century |
| 4 | Herpesviridae Infections (epidemiology) |
| 4 | Herpes Genitalis (epidemiology) |
| 4 | Herpes Genitalis (drug therapy) |
| 4 | Hepatitis C (blood) |
| 4 | Hepatitis B (immunology) |
| 4 | Hepacivirus (immunology) |
| 4 | Health Personnel (education) |
| 4 | Health Care Costs |
| 4 | HIV Seropositivity (transmission) |
| 4 | HIV Seropositivity (drug therapy) |
| 4 | HIV Protease (genetics) |
| 4 | Guideline Adherence |
| 4 | Gonorrhea (epidemiology) |
| 4 | Genes, Viral |
| 4 | Gastroenteritis (prevention & control) |
| 4 | Financing, Organized |
| 4 | Fear |
| 4 | Far East |
| 4 | Enzyme-Linked Immunosorbent Assay (methods) |
| 4 | Developing Countries (statistics & numerical data) |
| 4 | Data Collection (standards) |
| 4 | DNA Primers |
| 4 | Cross-Cultural Comparison |
| 4 | Cooperative Behavior |
